Bristol-Myers slumps, Merck shows gainsBristol-Myers Squibb, Co. and its cancer drug, Optivo, did not meet its primary goal. Click here for the complete story.Carlo Centeno2016-08-05T09:33:00-04:00August 5, 2016|Share This Story, Choose Your Platform!FacebookTwitterLinkedInRedditWhatsAppTumblrPinterestVkXingEmail About the Author: Carlo Centeno Related Posts Capital Markets Update Capital Markets Update Our Most Recent Newsletter Gallery Our Most Recent Newsletter Perspective & Commentary: Week of May 9, 2022 Gallery Perspective & Commentary: Week of May 9, 2022 2022 1st Quarter Newsletter, “Leading Investors” Gallery 2022 1st Quarter Newsletter, “Leading Investors” Leave A Comment Cancel replyComment Save my name, email, and website in this browser for the next time I comment.
Leave A Comment